ImPact Biotech
Tel Aviv, Israel· Est.
Israeli biotech leveraging VTP photodynamic therapy for minimally invasive tumor ablation across solid‑tumor indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli biotech leveraging VTP photodynamic therapy for minimally invasive tumor ablation across solid‑tumor indications.
OncologyImmunotherapy
Technology Platform
Vascular Targeted Photodynamic (VTP) therapy using intravenously administered Padeliporfin activated by non‑thermal laser light to ablate tumor vasculature and induce immunogenic cell death.
Opportunities
Expansion of the VTP platform into multiple solid‑tumor indications and combination regimens with immunotherapies could generate sizable market potential and partnership interest.
Risk Factors
Reliance on a single technology platform, regulatory uncertainties, and competition from other ablative and photodynamic therapies pose significant development risks.
Competitive Landscape
Key competitors include other photodynamic therapy developers (e.g., Photofrin, Talaporfin) and minimally invasive ablation technologies, but ImPact differentiates itself with a laser‑activated drug that offers precise vascular occlusion and immune activation.